(Co. Reg. No: 200405621W)

iX BIOPHARMA SECURES SOUTH KOREA PATENT FOR WAFERIX™ TECHNOLOGY

Singapore, 9 June 2016 – Homegrown specialty pharmaceutical company **iX Biopharma Ltd.** ("iX Biopharma" or, together with its subsidiaries, "the Group") is pleased to announce that it has been granted a patent in South Korea (no. 10-1612073) for its WaferiX™ drug delivery technology. The patent will expire on 26 October 2030.

The grant of the South Korean patent marks another milestone for iX Biopharma, following the success of a recent multi-dose, placebo-controlled clinical study that confirmed the safety and good tolerability of the Group's lead product, Wafermine™, the first ever oral-sublingual analgesic employing ketamine as an active compound.

WaferiX™ is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The WaferiX™ technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiX™ include rapid drug absorption and onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.

The claims of the patent cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity, and provide strategic coverage for iX Biopharma's WaferiX™ technology in South Korea. According to the claims of the patent, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also covered.

South Korea is the seventh country to grant iX Biopharma a patent for WaferiX™. The Group was recently granted patents in Japan and Indonesia in September and November 2015 respectively, while counterpart patents have already been granted in Singapore, Australia, New Zealand and Malaysia. Pending applications are currently under examination in the US, Europe, China, India, Canada, South Africa, Hong Kong, Thailand and Vietnam.

About iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with initial focus on the development and commercialisation of innovative therapies for pain management and men's health. The Company leverages its patented sublingual drug delivery technology, WaferiX™, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. It currently has three products under development – **Wafermine™** and **Wafernyl™** for pain management, and **PheoniX™** for erectile dysfunction.

Contact for media:

Ms Alvina Tan
DID: +65 6221 2123
H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg

Ms Karin Lai
DID: +65 6221 0081
H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg

This document has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, CIMB Bank Berhad, Singapore Branch, for compliance with the relevant rules of the SGX-ST. CIMB Bank Berhad, Singapore Branch, has not independently verified the contents of this announcement. This document has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Tony Toh, Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.